Private Equity Acquisition Marks End of Public Trading for Medical Device Maker
Avanos Medical has agreed to be acquired by American Industrial Partners in an all-cash transaction valued at $1.272 billion, the company announced, bringing an end to its tenure as a publicly traded medical device manufacturer. Under the terms of the agreement, Avanos shareholders will receive $25.00 per share—representing a substantial 72.1% premium over the company's previous closing price. The board of directors unanimously approved the transaction, which is expected to close during the second half of 2026, contingent on customary closing conditions and regulatory approvals.
The acquisition comes at a strategic inflection point for Avanos, occurring shortly after the company delivered better-than-expected fourth-quarter financial results. In Q4, Avanos reported adjusted earnings per share of 29 cents, beating the consensus estimate of 25 cents, while net sales reached $180.9 million compared to analyst expectations of $174.7 million. This outperformance underscores the operational momentum the company has built heading into its transition to private ownership.
Key Financial Details and Transaction Structure
The 72.1% premium over the previous closing price represents a significant value proposition for shareholders, reflecting American Industrial Partners' confidence in Avanos's business fundamentals and growth potential. The all-cash nature of the deal eliminates execution risk and provides immediate liquidity for equity holders, a critical consideration in the current macroeconomic environment where deal certainty carries substantial weight.
Avanos's financial metrics demonstrate the company's operational resilience:
- Q4 Adjusted EPS: 29 cents (beat consensus of 25 cents)
- Q4 Net Sales: $180.9 million (exceeded $174.7 million forecast)
- Acquisition Price Per Share: $25.00
- Total Deal Value: $1.272 billion
- Expected Closing: H2 2026
The company's ability to exceed earnings and revenue expectations in the period leading up to the acquisition announcement suggests that American Industrial Partners is acquiring a business with positive momentum and improving operational execution. This is particularly relevant given the increasing scrutiny private equity firms face regarding acquisition valuations in the current interest rate environment.
Market Context: Medical Device Sector and Private Equity Trends
The acquisition of Avanos Medical reflects broader trends in the medical device industry, where specialized manufacturers with focused product portfolios and strong market positions increasingly attract private equity interest. The healthcare sector has become a core target for buyout firms seeking stable, recurring revenue streams and opportunities to implement operational improvements away from public market scrutiny.
Avanos, which manufactures medical devices across critical care, surgical, and respiratory categories, fits the profile of an attractive private equity acquisition target. The company serves essential healthcare functions with products that demonstrate durable demand and pricing power. American Industrial Partners, known for its focus on industrials and healthcare companies, brings sector expertise and operational resources to support value creation during the private ownership phase.
The broader medical device sector has experienced consolidation pressure from rising healthcare costs, regulatory complexity, and the need for substantial capital investment in research and development. Going private allows companies like Avanos to pursue longer-term strategic initiatives without the quarterly earnings pressures that characterize public markets. The ability to reinvest cash flows and pursue acquisitions without immediate shareholder return expectations can unlock significant value over a multi-year holding period.
Competitors in adjacent medical device categories have similarly pursued private ownership or restructuring initiatives, signaling that the current environment favors companies capable of demonstrating consistent profitability and market position strength—both characteristics that Avanos demonstrated in its pre-acquisition results.
Investor Implications and Market Significance
For Avanos shareholders, the transaction provides certainty of value at a premium to recent trading levels, addressing potential concerns about competitive dynamics and healthcare sector headwinds. The unanimous board approval reflects director confidence that the $25.00 per share price represents fair value and appropriately compensates equity holders for the company's ongoing operations and future prospects.
The deal's expected H2 2026 closing timeline creates a window during which investors should monitor whether regulatory authorities in relevant jurisdictions raise substantive competitive or compliance concerns. Given the healthcare sector's regulatory environment, particularly regarding device safety and efficacy claims, any delays beyond the anticipated timeline would merit investor attention.
For the broader medical device investment thesis, this transaction signals that private equity sees attractive opportunities in the sector despite current challenges. The premium paid suggests confidence in Avanos's business model and management team's ability to drive operational improvements and strategic initiatives under private ownership. The all-cash structure also indicates sufficient confidence to avoid contingent consideration or earnout structures that might otherwise suggest uncertainty about forward-looking performance.
The acquisition removes a public equity float from the market and eliminates Avanos as an investment option for index and actively managed funds seeking medical device sector exposure. Investors with existing Avanos positions should consult their tax advisors regarding the timing and structure of transaction consideration, particularly regarding whether the $25.00 per share consideration qualifies for favorable tax treatment under applicable regulations.
Looking Forward
Avanos Medical's transition to private ownership under American Industrial Partners represents a strategic pivot toward long-term value creation outside the public markets. The timing of this acquisition—following strong operational results and reflecting robust market conditions for healthcare-focused private equity transactions—positions the company for potential operational improvements and strategic initiatives that may be constrained by public market dynamics.
The successful completion of this transaction will depend on satisfying closing conditions and regulatory approvals throughout 2026. For investors monitoring the medical device sector, this acquisition underscores the sector's continued attractiveness to sophisticated capital providers and the premium valuations available to companies demonstrating consistent profitability and market leadership in specialized medical device categories.